Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry скачать в хорошем качестве

Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

Is there a Bermuda Triangle of drug prices? Do FDA advisers matter? And when should biotech companies throw in the towel? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a Senate hearing that put major pharma CEOs in the same room with the middlemen they love to blame for rising drug prices, with mixed results. We also explain what is a massive week for Sarepta Therapeutics, the FDA, and the future of gene therapies for rare diseases, plus the latest news in the life sciences. More from STAT: Become a subscriber: https://www.statnews.com/stat-plus/ Watch Full Episodes: / @statnews Newsletters: https://www.statnews.com/signup/ STAT events: https://www.statnews.com/stat-events/ Facebook:   / statnews   Twitter:   / statnews   Instagram:   / statnews   Flipboard: rb.gy/3xnsxr STAT Reports: https://rb.gy/rexfwj STAT eBooks: https://rb.gy/eme3h5 ABOUT STAT: Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.